• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Interim Analysis of a Phase 3 Open-Label Study Indicates Safety and Efficacy of RBX2660, an Investigational Live Biotherapeutic, in a “Real-world” Population of Patients with Recurrent Clostridioides difficile Infection

Colleen Kraft MD1, Sahil Khanna MBBS2, Maha Assi MS MPH3, Paul Feuerstadt MD4, Adam Harvey PhD5, Lindy Bancke PharmD5
1Emory University, Atlanta, GA, USA; 2Mayo Clinic, Rochester, MN, USA; 3Infectious Disease Consultants, Wichita, KS, USA; 4Gastroenterology Center of Connecticut, Hamden, CT, USA; 5Rebiotix Inc, Roseville, MN, USA

Download the poster (2 MB)

Digestive Disease Week (DDW)
May 21-23, 2021

Background

  • Microbiota-restoring approaches are being widely evaluated for treatment of recurrent Clostridioides difficile infections (rCDI) in controlled clinical studies.
  • Eligibility criteria in clinical trials of investigational treatments are often narrowly defined, with rigid diagnostic criteria and exclusion of patients with potentially confounding co-morbid conditions, such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).
  • RBX2660, an investigational microbiota-based formulation, has shown efficacy in preventing rCDI through 8 weeks in several previous clinical trials, including two randomized, placebo-controlled studies (NCT02299570; NCT03244644).
  • Herein we report an interim analysis of PUNCH CD3-OLS, a Phase 3 open-label study evaluating the safety and efficacy of RBX2660 in the reduction of rCDI recurrence (NCT03931941).
  • PUNCH-CD3-OLS eligibility criteria is less restrictive to allow evaluation in a population more typical of real-world rCDI clinical practice.

Conclusions

  • RBX2660 demonstrated safety and efficacy under real world conditions for reduction of rCDI in adult participants following antibiotic therapy with a consistent and favorable safety profile for single or multiple doses of RBX2660.
  • These interim results replicate the safety and efficacy profile demonstrated in previous studies of RBX2660, contributing to the preponderance of evidence compiled over the formulation’s development program.
  • Furthermore, the observed RBX2660 safety and efficacy profile in a population inclusive of participants with IBD and IBS demonstrates that previously established results for RBX2660 remain robust in a broader population more typical of real-world rCDI clinical practice.
  • This study is ongoing and continues to enroll subjects.

Microbiota Restoration Therapy Posters Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT